

RACHITA PRAKASH
Rprakash@kidneyasc.com

EDUCATION

Bachelor of Medicine and Surgery (MBBS) 07/1999 - 02/2005
MAULANA AZAD MEDICAL COLLEGE New Delhi, India
MD, Internal Medicine 07/2006 – 06/2009
ROBERT PACKER HOSPITAL, GUTHRIE HEALTH SERVICES Sayre, PA
Fellow, Renal-Electrolyte Division 07/2010 – 06/2012
UNIVERSITY OF PITTSBURGH MEDICAL CENTER Pittsburgh, PA

CERTIFICATION

- ABIM Nephrology Participating in MOC 2022-present
- ABIM Internal Medicine Certified 8/2009,4/2019

PROFESSIONAL EXPERIENCE

Nephrologist 08/2017-present
KIDNEY ASSOCIATES OF COLORADO Denver, CO

- *Three physician expanding practice in Denver, CO*
- *Medical Director Acute Inpatient Dialysis Services Program at Centura Healthcare facilities*
- *Medical Director FMC JV Dialysis Unit*

Nephrologist 01/2016 -05/2017
KIDNEY SPECIALISTS, PLLC Martinsburg, WV

- *Two person expanding practice in Winchester VA and Eastern Panhandle, WV serving 2 tertiary care hospitals and 4 dialysis units*

Hospitalist 09/2014-12/2015
VIRGINIA EMERGENCY MEDICINE ASSOCIATES Fairfax, VA
INOVA FAIR OAKS HOSPITAL

Nephrologist 07/2012-07/2013
NORTHERN TIER NEPHROLOGY Kittanning, PA

- *Two-person practice in the Greater Pittsburgh Area serving 3 tertiary care hospitals and 2 joint venture dialysis units with a large outpatient base*

Fellow, Renal Electrolyte Division 07/2010-06/2012
UNIVERSITY OF PITTSBURGH MEDICAL CENTER (UPMC) Pittsburgh, PA
VA PITTSBURGH HEALTHCARE SYSTEM

- *Management of Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), Electrolyte Abnormalities, Hypertension*
- *In-hospital and outpatient hemodialysis and peritoneal dialysis experience*
- *Critical care nephrology including use of continuous renal replacement therapy (CRRT)*
- *Management of pre-operative and post-operative kidney transplant recipients*
- *Prescribing and managing complications of immunosuppression in transplant recipients*
- *Native and transplant kidney biopsies, insertion of temporary dialysis catheters*

Internal Medicine Resident/Chief Resident 07/2006-06/2009
ROBERT PACKER HOSPITAL, GUTHRIE HEALTH SERVICES Sayre, PA

TEACHING EXPERIENCE

Fellow

- *Instruction of medical students and internal medicine residents during renal clinical rotations*
- *Instruction of medical students in the art of physical examination*
- *Kidney Course for students, Internal Medicine residents*
- *Renal Grand Rounds, Journal Clubs*

Chief Resident

- *Conducting daily morning report*
- *Journal Club*
- *Internal Medicine Grand Rounds*

RESEARCH EXPERIENCE

Publications

- *Comparison of Survival of Patients with Heart and Lung Transplant on Peritoneal Dialysis and Hemodialysis* *Guru P. Perit Dial Intern 2014; 34*

Clinical Research

- (Principal Investigator) *Regen-007 trial - A Phase 2, Prospective, Randomized, Double-Arm, Open-label, Repeat Dose, Safety and Efficacy Study of Renal Autologous Cell Therapy (REACT) in Subjects with Type 1 or 2 Diabetes and Chronic Kidney Disease*
- (Principal Investigator) *Applause trial - A multi-center, randomized, double-blind, placebo controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients*
- (Principal Investigator) *PATH 1 - A phase 3 randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of dose-titrated PLS240 in the treatment of secondary hyperparathyroidism in individuals with End Stage Kidney Disease on hemodialysis (PATH-1) with an open-label extension*
- (Sub-investigator) *FALCON Phase III study for bardoxolone methyl in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)*
- (Sub-investigator) *SURMOUNT trial Phase 3, event-driven, multicenter, international, randomized, double-blind, placebo-controlled, parallel-group study. The study will assess the effect of tirzepatide at the maximum tolerated dose (10 mg or 15 mg QW) compared with placebo in people living with obesity: BMI >27 kg/m² and CVD-risk*
- (Sub--investigator) *FOCUS A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Dose Conversion from a Long-Acting Erythropoiesis-Stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects*
- (Sub-investigator) *Fibrogen Denali study : Phase 3b Multicenter, Open-Label Single Arm Study of Roxadustat: Either as Conversion from a Continuous Erythropoietin Receptor Activator (CERA), or as Initial Anemia Treatment in Hemodialysis (HD) Patients*
- (Sub-investigator) *Regen 002 A Phase II, Randomized, Open-Label, Placebo Controlled Safety and Efficacy Study of a Renal Autologous Cell Therapy (REACT) in Patients with Type 2 Diabetes and Chronic Kidney Disease*
- (Sub-investigator) *DIALIZE - An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Arrhythmia-Related Cardiovascular Outcomes in Participants on Chronic Hemodialysis with Recurrent Hyperkalemia (DIALIZE-Outcomes)*
- (Principal Investigator) *Single center retrospective analysis to compare mortality in incident chronic hemodialysis patients with incident peritoneal dialysis patients in the first 3 months of starting dialysis*
- (Principal Investigator) *Single center retrospective analysis to examine survival outcomes in hemodialysis patients with solid organ transplants*

Renal Grand Rounds

- *Cryoglobulinemic kidney disease in the HIV/HCV co-infected patient*
- *Bisphosphonates in Chronic Kidney Disease – A review*
- *Pregnancy in Kidney Transplantation with Chronic Kidney Disease*

Poster Presentations

- *Survival On HD After Non-Renal Solid Organ Transplant Is Poor* (Principal Author) UPMC. Presented NKF 2012
- *Outcome At 90 Days Of Dialysis* (Principal Author) UPMC. Presented at NKF 2012
- *Early Outcomes in HD and PD Incident Patients by Initial Access Types* (Principal Author) UPMC. Presented ADC 2012
- *Clinical Mimicry – Culture negative endocarditis vs systemic vasculitis.* (Principal Author) Robert Packer Hospital, Sayre, PA. Presented ACP 2008
- *Metamorphosis: Crescentic transformation with Anti GBM antibodies arising from Idiopathic Membranous Glomerulopathy.* (Principal Author) Robert Packer Hospital, Sayre, PA. Presented ACP 2008